Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA.
van Dijk AD, Hoff FW, Qiu Y, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, Jenkins GN, de Bont ESJM, Kornblau SM, Horton TM.
van Dijk AD, et al. Among authors: alonzo ta.
Proteomics Clin Appl. 2022 Mar;16(2):e2100072. doi: 10.1002/prca.202100072. Epub 2021 Nov 17.
Proteomics Clin Appl. 2022.
PMID: 34719869
Free PMC article.
Clinical Trial.